Using systemically delivered siRNAs, KRAS as a target of KRAS siRNA was silenced which regulated cellular proliferation and survival in lung and colon adenocarcinoma treatment (Pecot et al., 2014; Ying et al., 2016). Here, KRAS is linked to colon adenocarcinoma.